My view (opinion only) is that these results are highly unlikely to be negative and that should trigger a re-rating as much on the implications for the CHF trial as for the potential commercialization for LVAD. We are all gambling here but I think the share price still lags real value given the reduction in risk and increase in potential earnings we have seen over the past two months or so.
Ann: End-Stage HF Results Selected For AHA Scientific Sessions, page-52
-
- There are more pages in this discussion • 36 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.15 |
Change
0.000(0.00%) |
Mkt cap ! $1.295B | |||
| Open | High | Low | Value | Volume |
| $1.15 | $1.16 | $1.13 | $1.373M | 1.202M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 19 | 30559 | $1.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.15 | 11447 | 6 |
View Market Depth
| Last trade - 12.44pm 22/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |